nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-5965C333·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Observational cohort study

Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden.

Xia et al.Xia, Eriksdotter, Clark et al.·2026·PharmacoEconomics·10.1007/s40273-026-01612-5 ↗

Primary claim

The average lifetime costs of formal care for AD dementia were 2,440,000 SEK compared with 510,000 SEK for matched controls, resulting in a difference of 1,930,000 SEK.

Supported · an eight-year proxy with sparse long follow-up, restricted matching, and potentially biased control truncation
In brief

Swedish register linkage yields useful stage-specific care estimates, but the headline lifetime cost rests on an eight-year proxy with sparse long follow-up.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect is as large as stated. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

INTRODUCTION: The study aimed to estimate the utilization and lifetime costs of formal care for individuals with Alzheimer's disease (AD) dementia in Sweden.

METHODS: We used longitudinal data from 20,366 individuals (mean age: 78.54 years) diagnosed with AD dementia from the Swedish Register of Cognitive/Dementia Disorders linked to other registers to derive data on formal care utilization, including inpatient and outpatient specialist care, prescribed drugs, and social care. We estimated formal care utilization across AD dementia stages defined by the Mini-Mental State Examination and the lifetime formal care costs (in 2023 Swedish krona, SEK) in patients with AD dementia using the Zhao and Tian estimator, which uses the inverse probability weighting technique to account for censoring due to loss to follow-up. The estimates of lifetime costs were compared with those of controls matched to patients with AD dementia by birth year, sex, and region of residence at the time of diagnosis.

RESULTS: The number of outpatient specialist visits decreased as AD severity increased, while the number of drug prescriptions and social care utilization increased with advancing AD stages. The estimated lifetime costs of formal care for AD dementia were 2,440,000 SEK (€212,174; $US230,189; 95% CI 2,088,000-2,793,000 SEK), compared with 510,000 SEK (€44,348; $US48,113; 95% CI 482,000-539,000 SEK) for matched controls.

CONCLUSIONS: This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. These findings will provide inputs for future economic evaluations of treatments and preventive interventions for AD dementia.

Key Claims

Primary finding · Supported

The average lifetime costs of formal care for AD dementia were 2,440,000 SEK compared with 510,000 SEK for matched controls, resulting in a difference of 1,930,000 SEK.

Fragile — the claim's weakest requirement is that the effect is as large as stated. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

an eight-year proxy with sparse long follow-up, restricted matching, and potentially biased control truncation

Results, Lifetime Costs of AD Dementia
Secondary · Well-supported

The number of outpatient specialist visits decreased as AD severity increased, while the number of drug prescriptions and social care utilization increased with advancing AD stages.

direct stage-specific register estimates with bootstrapped confidence intervals in Table 3

Abstract, Results; Table 3
Quote verified
Secondary · Tentative

These findings can be generalizable to other Nordic countries, considering their similar healthcare system structures.

single-country Swedish data and local care costs do not directly establish Nordic transferability

Discussion, implications paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Large linked register-based patient cohort

The study links SveDem with national healthcare and social-care registers for 20,366 people diagnosed with AD dementia, enabling resource estimates across medical and municipal care.

↳ Methods, Study Design and Study Population; Measurements of HCRU

#contribution

Granular utilization across dementia stages

Table 3 reports annual utilization across very mild, mild, moderate, and severe AD dementia, including specialist visits, prescriptions, home care, and institutionalization.

↳ Results, HCRU and Annual Costs of Formal Care by AD Dementia Stages; Table 3

#positioning

Limitations traced to bias direction

The discussion explains how omitted primary care, finite follow-up, control truncation, and informative censoring could affect the magnitude or direction of the estimates.

↳ Discussion, limitations paragraph

Limitations

#methodological rigour

Lifetime estimate is an eight-year proxy

The headline 2.44-million-SEK estimate represents accumulated costs over a maximum of eight years, while median follow-up was 1.88 years and only 1.37% were observed for at least seven years.

↳ Methods, Statistical Analysis; Results, Lifetime Costs of AD Dementia

#methodological rigour

Comparator difference may be upward biased

Controls were matched only on birth year, sex, and region, and their follow-up was truncated with that of cases. The discussion acknowledges that truncation may overestimate the AD–control cost difference.

↳ Methods, Study Design and Study Population; Discussion, limitations paragraph

#application pathway

Nordic transferability remains unvalidated

The extension to other Nordic countries rests on broadly similar healthcare structures rather than direct cross-country evidence, despite country-specific unit costs and service organization.

↳ Table 1; Discussion, implications paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The main contribution is the combination of stage-specific utilization data with accumulated formal-care costs from linked Swedish registers. Methodological execution is generally competent, but the lifetime estimate is an eight-year proxy supported by limited long-duration observation and a non-informative-censoring assumption. The matched comparison is further constrained by restricted matching and follow-up truncation, which the discussion says may overestimate the cost difference. The paper’s detailed limitation analysis supports its contextual score, while the unqualified lifetime wording and Nordic generalization prevent a stronger assessment.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.6±0.2

Contribution
3.6

The study adds stage-specific formal-care utilization and an accumulated post-diagnosis cost estimate to prior Swedish annual-cost work. The advance is meaningful but remains an incremental, country-specific descriptive contribution.

Introduction; Discussion, paragraphs 3–4

“The present study differs by further subdividing the mild AD dementia stage into very mild and mild AD dementia stages.”

Methodological Rigour
3.5

Register linkage, explicit MMSE stages, bootstrapped intervals, and the Zhao–Tian estimator fit the descriptive objectives. Confidence in the lifetime comparison is reduced by short follow-up, censoring assumptions, control truncation, limited matching, and the absence of reported sensitivity analyses for these assumptions.

Methods, Statistical Analysis; Results, Lifetime Costs of AD Dementia; Discussion, limitations paragraph

“The 8-year accumulated costs were used as a proxy for lifetime costs.”

Reporting
3.8

The paper follows a coherent progression from register linkage and stage definitions to utilization and accumulated-cost results. The abstract and conclusion nevertheless use “lifetime costs” without retaining the central qualification that the estimate is an eight-year proxy.

Abstract, Results and Conclusions; Methods, Statistical Analysis

“The 8-year accumulated costs were used as a proxy for lifetime costs.”

Positioning
3.8

The discussion compares findings with Swedish and Nordic cost studies and traces several limitations to likely directions of bias. Contextualization is constrained by an unvalidated Nordic generalization and by conclusions that do not retain the stated uncertainty around the matched-control difference.

Discussion, paragraphs 2–6; Conclusions

“This may have led to overestimation of the difference between lifetime costs of care.”

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The conversion of annual daytime-activity unit costs to utilization measured in days is not explained, and the malformed five-year follow-up count is consistent with 2,106 participants; neither establishes a changed cost result.

Ethics approval: declared · Data availability: not stated · Code availability: not stated

Reference IntegrityClean

32 references in manuscript 27 of 27 checkable references found in an index 5 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The lifetime cost claim is estimated from nationwide real-world population register data on 20,366 patients with matched controls over up to eight years, though it has not been independently replicated.

From the paper
“These findings will provide inputs for future economic evaluations of treatments and preventive interventions for AD dementia.”

The paper names a concrete downstream use of its cost estimates, supporting economic evaluations that inform treatment and prevention decisions, but does not say who would act on them.

Pathway

Health economists and technology assessment bodies would use these stage-specific and lifetime cost estimates as inputs to evaluate and guide funding of Alzheimer's treatments and preventive interventions.

Barrier

The estimates exclude primary care and informal care, proxy lifetime costs with an eight-year horizon, and reflect Sweden's specific care system, limiting completeness and transferability.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  2. The potential of low-field MRI for global dementia care

    2026 · Clinical medicine

    Primary claim

    Studies demonstrate reliable detection of core Alzheimer disease markers, including hippocampal atrophy and white matter hyperintensities, on portable low-field systems, with promising correspondence to conventional high-field MRI findings.

    Tentative
    Evidence Score
    3.7±0.1
    Reliability
    Caveats
  3. UK Biobank at 20 - a growing, global resource for dementia research

    2026 · Clinical medicine

    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →